

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

COALITION FOR AFFORDABLE DRUGS X LLC,
Petitioner,

v.

ANACOR PHARMACEUTICALS, INC.,
Patent Owner.

Case No. IPR2015-01776
Patent No. 7,582,621

**DECLARATION OF PAUL J. REIDER, PH.D., IN SUPPORT OF
PATENT OWNER RESPONSE**

TABLE OF CONTENTS

	<u>Page</u>
I. INTRODUCTION	1
II. ACADEMIC AND PROFESSIONAL QUALIFICATIONS	1
III. SCOPE AND SUMMARY OF THE OPINION	4
IV. TECHNICAL BACKGROUND	6
A. Organic Chemistry Tutorial	6
1. Aliphatic and Aromatic Molecules	7
2. Heterocycles.....	8
3. Substituted Carbon Molecules	11
a) Halogens	12
b) Boron-Containing Substituents	14
(1) Boranes and Organoboranes.....	15
(2) Borinic acids.....	17
(3) Boronic Acids.....	17
(4) Borate Esters and Borate Anion Complexes.....	18
B. The Multi-Dimensional Challenge of Drug Development	20
1. Selected Desirable Biochemical and Physical Properties For Pharmaceuticals.....	26
a) Absence of Toxicity at Therapeutic Doses.....	26
b) Selectivity	28
c) Potency	30
d) Stability.....	32

e)	Hydrophilicity/Lipophilicity.....	33
f)	Tavorole Confirms These Principles	34
2.	Compound Identification	35
3.	Small Structural Changes Have Unpredictable and Dramatic Biological Effects.....	36
4.	A POSA in 2005 Rarely Would Have Considered Boron- Containing Compounds as Drug Candidates	38
a)	A POSA in 2005 Would Not Have Expected Boron-Containing Compounds To Be Non-Toxic	39
b)	A POSA in 2005 Would Not Have Expected Boron-Containing Compounds To Be Selective	42
c)	VELCADE [®] Was a Warning to POSAs in the Early 2000s About the Toxicity of Boron- Containing Compounds	46
V.	THE '621 PATENT.....	46
VI.	LEVEL OF ORDINARY SKILL IN THE ART	48
VII.	CLAIM CONSTRUCTION	49
VIII.	OVERVIEW OF THE CITED REFERENCES.....	50
A.	Austin	50
B.	Brehove.....	55
C.	Freeman	57
IX.	RESPONSE TO PETITIONER'S GROUNDS 1 AND 2.....	59
A.	Ground 1: Claims 1-12 Are Not Obvious Over Austin and Brehove.....	59
1.	Austin	59

a)	A 2005 POSA Would Not Consider Austin to be Relevant	59
b)	Austin Does Not Provide an Expectation of Success in Using Boron-Containing Compounds to Treat Onychomycosis	63
c)	A POSA Would Not Have Selected Tavaborole from the Many “Preferred” Compounds of Austin	63
2.	Brehove	65
a)	Brehove Is Not Credible	65
3.	A 2005 POSA Would Not Have Been Motivated to Combine Austin with Brehove.....	73
a)	The Proposed Combination Lacks Data that Would Have Provided a POSA with an Expectation of Success.....	73
b)	The Benzoxaboroles of Austin and the Dioxaborinanes of Brehove Are Structurally Dissimilar	74
c)	Brehove Would Not Have Supplied a Reasonable Expectation of Success and Does Not Make Tavaborole Obvious to Try.....	77
B.	Ground 2: Claims 1-12 Are Not Obvious Over Austin and Freeman	78
1.	Austin	78
2.	Freeman.....	78
a)	A 2005 POSA Would Not Have Considered Freeman’s Compounds To Be Effective Against Microorganisms	78
b)	A 2005 POSA Would Have Expected the Phenyl Boronic Acids of Freeman To Be Toxic to Mammals	81

3. A 2005 POSA Would Not Have Been Motivated to Combine Austin with Freeman 83

4. Freeman Would Not Have Supplied a Reasonable Expectation of Success and Does Not Make Tavaborole Obvious To Try..... 86

5. Dr. Murthy’s and Dr. Kahl’s Theory Would Have Led a 2005 POSA To Expect Tavaborole To Be Inactive Against Microorganisms and Toxic to Mammals 86

X. IT WOULD HAVE BEEN UNEXPECTED IN 2005 AND REMAINS SO TODAY THAT TAVABOROLE IS BOTH SAFE AND EFFECTIVE FOR TREATING ONYCHOMYCOSIS IN HUMANS 88

XI. CONCLUSION..... 89

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.